In Vivo Positive Magnetic Resonance Imaging of Brain Cancer (U87MG) Using Folic Acid-Conjugated Polyacrylic Acid-Coated Ultrasmall Manganese Oxide Nanoparticles

ABSTRACTThe development of nanomaterials, especially the development of multi-modality imaging nanoprobe technology has become a reality for tumor imaging diagnosis. In this study, the gadolinium ion chelating agent (2,2′,2′′-(10-(2-(2, 5-dioxopyrrolidin-1-oxyl)-2 oxoethyl)-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7-tri)triacetic acid) (DOTA-NHS) and polyethylene glycol (PEG)-modified targeting ligand PEG-folic acid (FA) were grafted onto the PEG-modified fifth-generation polyamide-amine dendrimer (P5-NH2), which were undertaken as standards to wrap gold nanoparticles. Then, remaining amino group was acetylated to acquire Gd–Au DENPS-FA nanoparticles. Biocompatibility and cytotoxicity of nanoparticles were analyzed while characterizing them. The cases with unidentified tumors (mass diameter >4.5 cm) of abdominal or pelvic origin were selected and used for clinical study of computed tomography (CT)/magnetic resonance imaging (MRI) dual-modality abdominal tumors. In the test, average particle size of Gd-Au DENPs-FA nanoparticles was 4.2 nm, and they had good water solubility and stability in aqueous solution. When concentration of Au+ nanoparticles increased, the cell morphology remained normal, only a small number of round cells appeared, and the cell activity remained above 80%. GD-Au DENPs-FA nanoparticles had a good targeting specificity for KB cells with high folate receptor expression. During 6–24 hours of injection, the signal at the tumor site of the patient was enhanced markedly, namely the targeted gold nanoparticles were bound to the tumor tissue and the metabolic rate was slow. Based on this material, CT/MRI imaging could be performed in the patient’s body and further used for the early diagnosis of abdominal tumors.

Download Full-text

A New Potential Contrast Agent for Magnetic Resonance Imaging: Iron Oxide-4A Nanocomposite

Journal of Biomedical Physics and Engineering ◽

10.31661/jbpe.v0i0.755 ◽

2019 ◽

Cited By ~ 1

Author(s):

L Zareei ◽

B Divband ◽

A Mesbahi ◽

M Khatamian ◽

A Kiani ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Iron Oxide ◽

Magnetic Resonance ◽

Contrast Agent ◽

Contrast Agents ◽

Particle Diameter ◽

Average Particle ◽

Relaxation Rates ◽

Resonance Imaging ◽

T1 And T2

Background: Magnetic resonance imaging (MRI) contrast agents have an important role to differentiate healthy and diseased tissues. Access and design new contrast agents for the optimal use of MRI are necessary. This study aims to evaluate iron oxide–4A nanocomposite ability to act as a magnetic resonance imaging contrast agent.Materials and Methods: Iron oxide–4A nanocomposite (F4A) was synthesized. MTT assay was used to consider the nanocomposite safety for cell culture. The T1 and T2 relaxation times were measured using a 1.5 Tesla clinical MRI scanner. Then the corresponding relaxivities were determined.Results: The average particle diameter of the nanocomposite was 50 to 100 nm based on scanning electron microscope (SEM) image. A linear relationship between relaxation rates and the Fe concentration of the nanocomposite was obtained. The T1 and T2 relaxivities of the nanocomposite were calculated 5.413 and 1092.1 mM-1.s-1, respectively which led to the T2/T1 relaxivity ratioof 201.75.Conclusion: The high T2/T1 relaxivity ratio of the iron oxide–4A nanocomposite confirms it’s potential to act as a T2 contrast agent.

Download Full-text

A New Potential Contrast Agent for Magnetic Resonance Imaging: Iron Oxide-4A Nanocomposite

Journal of Biomedical Physics and Engineering ◽

10.31661/jbpe.v9i2apr.755 ◽

2019 ◽

Vol 9 (2Apr) ◽

Cited By ~ 1

Author(s):

L Zareei ◽

B Divband ◽

A Mesbahi ◽

M Khatamian ◽

A Kiani ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Iron Oxide ◽

Magnetic Resonance ◽

Contrast Agent ◽

Contrast Agents ◽

Particle Diameter ◽

Average Particle ◽

Relaxation Rates ◽

Resonance Imaging ◽

T1 And T2

Background: Magnetic resonance imaging (MRI) contrast agents have an important role to differentiate healthy and diseased tissues. Access and design new contrast agents for the optimal use of MRI are necessary. This study aims to evaluate iron oxide–4A nanocomposite ability to act as a magnetic resonance imaging contrast agent.Materials and Methods: Iron oxide–4A nanocomposite (F4A) was synthesized. MTT assay was used to consider the nanocomposite safety for cell culture. The T1 and T2 relaxation times were measured using a 1.5 Tesla clinical MRI scanner. Then the corresponding relaxivities were determined.Results: The average particle diameter of the nanocomposite was 50 to 100 nm based on scanning electron microscope (SEM) image. A linear relationship between relaxation rates and the Fe concentration of the nanocomposite was obtained. The T1 and T2 relaxivities of the nanocomposite were calculated 5.413 and 1092.1 mM-1.s-1, respectively which led to the T2/T1 relaxivity ratioof 201.75.Conclusion: The high T2/T1 relaxivity ratio of the iron oxide–4A nanocomposite confirms it’s potential to act as a T2 contrast agent.

Download Full-text

A Novel Paramagnetic Nanoparticle T 2 Magnetic Resonance Imaging Contrast Agent With High Colloidal Stability: Polyacrylic Acid‐Coated Ultrafine Dysprosium Oxide Nanoparticles

Bulletin of the Korean Chemical Society ◽

10.1002/bkcs.12074 ◽

2020 ◽

Vol 41 (8) ◽

pp. 829-836

Author(s):

Shanti Marasini ◽

Huan Yue ◽

Son Long Ho ◽

Hyunsil Cha ◽

Ji Ae Park ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Contrast Agent ◽

Polyacrylic Acid ◽

Colloidal Stability ◽

Oxide Nanoparticles ◽

Resonance Imaging ◽

Dysprosium Oxide ◽

Magnetic Resonance Imaging Contrast ◽

Imaging Contrast Agent

Download Full-text

Hemorrhage after particle embolization of hemangioblastomas: comparison of outcomes in spinal and cerebellar lesions

Journal of Neurosurgery ◽

10.3171/jns.2007.106.6.994 ◽

2007 ◽

Vol 106 (6) ◽

pp. 994-998 ◽

Cited By ~ 57

Author(s):

Jan Frédérick Cornelius ◽

Jean Pierre Saint-Maurice ◽

Damien Bresson ◽

Bernard George ◽

Emmanuel Houdart

Keyword(s):

Magnetic Resonance Imaging ◽

Spinal Cord ◽

Magnetic Resonance ◽

Particle Diameter ◽

Preoperative Embolization ◽

Resonance Imaging ◽

Selective Angiography ◽

Gelatin Microspheres ◽

Cerebellar Lesions ◽

Tumor Bleeding

Object In this study the authors compare the clinical outcomes after particle embolization of hemangioblastomas in the cerebellum and spinal cord. They also review the literature of similar cases. Methods Seven patients with hemangioblastomas in the spinal cord (four patients) and cerebellum (three patients) underwent preoperative embolization at the authors' center. Magnetic resonance imaging and selective angiography studies as well as histological diagnoses were available in all patients. Embosphere particles (trisacryl gelatin microspheres) were used in all cases. The smallest particle diameter ranged from 100 to 300 μm at the beginning of embolization in all patients. The outcome of embolization was favorable in patients with spinal cord hemangioblastomas, but it was unfavorable for those with cerebellar hemangioblastomas; acute tumor bleeding and death occurred in all of the latter cases. The outcomes following embolization are very different for these two locations possibly because of the different capillary sizes. Conclusions The authors no longer use particle embolization to treat cerebellar hemangioblastomas.

Download Full-text